| Primary |
| Acute Myeloid Leukaemia |
37.9% |
| Product Used For Unknown Indication |
36.2% |
| Drug Use For Unknown Indication |
10.3% |
| Acute Myeloid Leukaemia Recurrent |
8.6% |
| Prophylaxis Against Graft Versus Host Disease |
3.4% |
| Leukaemia Recurrent |
1.7% |
| Non-hodgkin's Lymphoma |
1.7% |
|
| Respiratory Distress |
27.3% |
| Thrombocytopenia |
27.3% |
| Fear Of Disease |
9.1% |
| Hypothermia |
9.1% |
| Stem Cell Transplant |
9.1% |
| Visual Disturbance |
9.1% |
| White Blood Cell Count Decreased |
9.1% |
|
| Secondary |
| Acute Myeloid Leukaemia |
22.0% |
| Peripheral T-cell Lymphoma Unspecified |
14.4% |
| Product Used For Unknown Indication |
11.0% |
| Burkitt's Lymphoma |
10.1% |
| Acute Lymphocytic Leukaemia |
7.8% |
| Prophylaxis |
6.5% |
| Drug Use For Unknown Indication |
4.3% |
| Mantle Cell Lymphoma |
3.1% |
| Angioimmunoblastic T-cell Lymphoma |
2.5% |
| Non-hodgkin's Lymphoma |
2.4% |
| Precursor T-lymphoblastic Lymphoma/leukaemia |
2.3% |
| Prophylaxis Against Graft Versus Host Disease |
2.1% |
| Lymphocytic Leukaemia |
2.0% |
| Acute Myeloid Leukaemia Recurrent |
1.7% |
| T-cell Lymphoma |
1.6% |
| Infection Prophylaxis |
1.5% |
| Stem Cell Transplant |
1.4% |
| Immunosuppression |
1.2% |
| Acute Leukaemia |
1.0% |
| Adult T-cell Lymphoma/leukaemia |
1.0% |
|
| Septic Shock |
14.7% |
| Sepsis |
10.2% |
| Renal Impairment |
8.3% |
| Pyrexia |
6.8% |
| Thrombocytopenia |
6.4% |
| Neutropenia |
6.0% |
| Neutropenic Sepsis |
5.3% |
| Thrombotic Thrombocytopenic Purpura |
4.5% |
| Urinary Tract Infection |
4.5% |
| Pneumonia |
3.8% |
| White Blood Cell Count Decreased |
3.8% |
| Intracranial Hypotension |
3.4% |
| Toxicity To Various Agents |
3.4% |
| Vomiting |
3.4% |
| Acute Myeloid Leukaemia |
2.6% |
| Febrile Neutropenia |
2.6% |
| Syncope |
2.6% |
| Urinary Incontinence |
2.6% |
| Wernicke's Encephalopathy |
2.6% |
| Hypophosphataemia |
2.3% |
|
| Concomitant |
| Acute Myeloid Leukaemia |
26.6% |
| Product Used For Unknown Indication |
9.6% |
| Drug Use For Unknown Indication |
8.8% |
| Acute Lymphocytic Leukaemia |
7.8% |
| Prophylaxis |
6.6% |
| Prophylaxis Against Graft Versus Host Disease |
5.6% |
| Stem Cell Transplant |
4.0% |
| Bone Marrow Conditioning Regimen |
3.3% |
| Chemotherapy |
3.1% |
| Multiple Myeloma |
2.9% |
| Peripheral T-cell Lymphoma Unspecified |
2.9% |
| Diffuse Large B-cell Lymphoma |
2.8% |
| B-cell Lymphoma |
2.1% |
| Chronic Myeloid Leukaemia |
2.1% |
| Cord Blood Transplant Therapy |
2.1% |
| Pain |
2.1% |
| Leukaemia |
2.0% |
| Nausea |
2.0% |
| Bone Marrow Transplant |
1.8% |
| Non-hodgkin's Lymphoma |
1.8% |
|
| Vomiting |
14.0% |
| Thrombocytopenia |
13.1% |
| Thrombotic Microangiopathy |
6.5% |
| Pyrexia |
5.6% |
| Rash |
5.6% |
| Renal Failure |
5.6% |
| Haemolysis |
4.7% |
| Acute Myeloid Leukaemia |
3.7% |
| Drug Ineffective |
3.7% |
| Pneumonia |
3.7% |
| Progressive Multifocal Leukoencephalopathy |
3.7% |
| Sepsis |
3.7% |
| Septic Shock |
3.7% |
| Tachypnoea |
3.7% |
| Transient Ischaemic Attack |
3.7% |
| Vulvovaginal Pruritus |
3.7% |
| Hepatotoxicity |
2.8% |
| Neutropenia |
2.8% |
| Subarachnoid Haemorrhage |
2.8% |
| Tachycardia |
2.8% |
|
| Interacting |
| Acute Myeloid Leukaemia |
100.0% |
|
|
